

Establishing selection criteria for male New Zealand White rabbits in interventional radiology research using organ volumes and vessel diameters

ELECTRONIC SUPPLEMENTARY MATERIAL

Table S1 Sensitivity analysis

Parameter	<i>n</i>	β (age × weight)	95% confidence interval	<i>p</i> -value (age × weight)
Liver	47	0.640	[-2.077 ; 3.357]	0.637
Right kidney	49	0.045	[-0.242 ; 0.333]	0.753
Left kidney	48	0.247	[-0.150 ; 0.653]	0.228
Spleen	23	-0.112	[-0.348 ; 0.124]	0.333
Trachea	19	0.073	[-0.378 ; 0.524]	0.735
Right common carotid artery	19	-0.035	[-0.278 ; 0.209]	0.766
Left common carotid artery	19	< 0.001	[-0.280 ; 0.280]	0.998
Superior vena cava	19	-0.082	[-0.487 ; 0.322]	0.671
Inferior vena cava	19	-0.267	[-0.519 ; -0.016]	0.038*
Celiac trunk	19	-0.047	[-0.281 ; 0.188]	0.676
Common hepatic artery	19	0.043	[-0.117 ; 0.203]	0.577
Superior mesenteric artery	19	-0.091	[-0.287 ; 0.105]	0.338
Right renal artery	19	0.072	[-0.179 ; 0.322]	0.551
Left renal artery	19	0.061	[-0.101 ; 0.223]	0.435
Abdominal aorta	19	0.055	[-0.143 ; 0.252]	0.564
Right common iliac artery	19	-0.062	[-0.199 ; 0.076]	0.354
Left common iliac artery	19	0.044	[-0.088 ; 0.176]	0.485
Right external iliac artery	19	0.036	[-0.074 ; 0.147]	0.491
Left external iliac artery	19	0.029	[-0.104 ; 0.163]	0.646
Right internal iliac artery	16	-0.090	[-0.182 ; 0.001]	0.053
Left internal iliac artery	17	-0.046	[-0.129 ; 0.036]	0.243
Right femoral artery	19	0.065	[-0.102 ; 0.233]	0.417
Left femoral artery	19	0.068	[-0.082 ; 0.217]	0.350

Interaction models ($Y \sim \text{age} + \text{body weight} + \text{age} \times \text{body weight}$) were used to assess whether age modifies weight-to-anatomy relationships. Significant *p*-values are indicated by an asterisk (*).

Table S2 Characteristics of New Zealand White rabbits in interventional oncology research. Rapid scoping review of male New Zealand White rabbits included in interventional oncology studies reporting on age and/or weight published within the last 10 years (01/2016 to 01/2026)

Reference	Tumor model	<i>n</i> (rabbits)	Sex	Body weight	Age
Elkhadragy et al. [24]	VX2 liver	16	male	2.7 – 3.2 kg	
Berz et al. [25]	VX2 liver	24	male	2.5 – 4 kg	
Cheng et al. [26]	VX2 liver	16	male	2.0 – 2.5 kg	8 weeks
Thompson et al. [27]	VX2 flanks	16	male	≈ 3 kg	
Shi et al. [28]	VX2 liver	36	male	2.0 – 2.5 kg	
Kim et al. [29]	VX2 liver	20	male	2.9 – 3.4 kg	
Borde et al. [30]	VX2 liver	12	male	4.3 ± 0.2 kg	
Savic et al. [15]	VX2 liver	21	male	2.5 – 4 kg	11 – 17 weeks
Savic et al. [17]	VX2 liver	32	male	2.4 – 4 kg	
Zhang et al. [31]	VX2 liver	10	male	2 – 2.5 kg	3 – 4 months (≈ 13 – 17 weeks)
Luo et al. [32]	VX2 sciatic nerve	26	male	2.0 – 2.5 kg	
Ludwig et al. [33]	VX2 liver	10	male	3.3 – 4.19 kg	
Attaluri et al. [34]	VX2 liver	10	male	4.0 – 4.5 kg	

- 24 Elkhadragy L, Khabbaz RC, Muchiri RN et al (2022) Pharmacokinetics and Early Tumor Response to Conventional Transarterial Chemoembolization with Sorafenib and Doxorubicin in a VX2 Rabbit Tumor Model. *J Vasc Interv Radiol* 33:1213-1221 e1215. <https://doi.org/10.1016/j.jvir.2022.07.011>
- 25 Berz AM, Santana JG, Iseke S et al (2022) Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model. *J Vasc Interv Radiol* 33:764-774 e764. <https://doi.org/10.1016/j.jvir.2022.03.026>
- 26 Cheng Z, Qin H, Cao W et al (2023) Intravoxel incoherent motion imaging used to assess tumor microvascular changes after transarterial chemoembolization in a rabbit VX2 liver tumor model. *Front Oncol* 13:1114406. <https://doi.org/10.3389/fonc.2023.1114406>
- 27 Thompson EA, Fowlkes NW, Jacobsen MC, Layman RR, Cressman ENK (2023) Quantitative Dual-Energy CT Image Guidance for Thermochemical Ablation: In Vivo Results in the Rabbit VX2 Model. *J Vasc Interv Radiol* 34:782-789. <https://doi.org/10.1016/j.jvir.2022.12.026>
- 28 Shi Q, Li T, Huang S et al (2021) Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8(+) T-Cell Infiltration in Rabbit VX2 Liver Tumor. *Cancer Manag Res* 13:6943-6952. <https://doi.org/10.2147/CMAR.S328294>
- 29 Kim GM, Kim MD, Kim do Y et al (2016) Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect. *J Vasc Interv Radiol* 27:1086-1092. <https://doi.org/10.1016/j.jvir.2016.02.032>
- 30 Borde T, Laage Gaupp F, Geschwind JF et al (2020) Idarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment. *J Vasc Interv Radiol* 31:1706-1716 e1701. <https://doi.org/10.1016/j.jvir.2020.04.010>
- 31 Zhang L, Wang N, Mao J et al (2018) Dual-Energy CT-Derived Volumetric Iodine Concentration for the Assessment of Therapeutic Response after Microwave Ablation in a Rabbit Model with Intrahepatic VX2 Tumor. *J Vasc Interv Radiol* 29:1455-1461. <https://doi.org/10.1016/j.jvir.2018.04.019>
- 32 Luo X, Qin Z, Tao H et al (2017) The Safety of Irreversible Electroporation on Nerves Adjacent to Treated Tumors. *World Neurosurg* 108:642-649. <https://doi.org/10.1016/j.wneu.2017.09.049>
- 33 Ludwig JM, Xing M, Gai Y, Sun L, Zeng D, Kim HS (2017) Targeted Yttrium 89-Doxorubicin Drug-Eluting Bead-A Safety and Feasibility Pilot Study in a Rabbit Liver Cancer Model. *Mol Pharm* 14:2824-2830. <https://doi.org/10.1021/acs.molpharmaceut.7b00336>

34 Attaluri A, Seshadri M, Mirpour S et al (2016) Image-guided thermal therapy with a dual-contrast magnetic nanoparticle formulation: A feasibility study. *Int J Hyperthermia* 32:543-557.
<https://doi.org/10.3109/02656736.2016.1159737>